CHEPLAPHARM ACQUIRES GEMZAR® FROM LILLY   Binningen/Greifswald, 16 December 2024  With the purchase of Gemzar® from Eli Lilly and Company, which was signed on 2 October 2024 and closed on 13 December 2024, the CHEPLAPHARM Group is once again expanding its existing portfolio in the oncology sector. The transaction includes the transfer of worldwi [ … ]

SEBASTIAN BRAUN WINS EY ENTREPRENEUR OF THE YEAR Greifswald, 08. November 2024 Sebastian Braun wins prestigious entrepreneur award in the ‘family business’ category First award winner from the eastern German states since 2014 The EY Entrepreneur of the Year Award is presented in 60 countries   Sebastian Braun, Chairman of the Supervisory Board, [ … ]

Artem Gevorkyan joins as Managing Director Corporate Business Development Karl ‘Charly’ Lang is entrusted with an extended area of responsibility and now leads the Supply Chain & Logistics division across the whole Group Klaus Köhl, previously COO, is leaving the company at his own request The globally active CHEPLAPHARM Group, headquartered  [ … ]

CHEPLAPHARM CLOSES FINANCIAL YEAR 2023 WITH RECORD REVENUE AND DOUBLE-DIGIT GROWTH Greifswald, 26th April 2024 Double-digit revenue growth again: +17% YoY to € 1,498.4 million (FY2022: € 1,279.5 million) EBITDA increases significantly by +14% YoY to € 780.5 million (FY2022: € 685.7 million) EBITDA margin remains at a high and industry-leading le [ … ]

Greifswald / Levallois-Perret, 03. April 2024Caroline Jacquin will take over the management of CHEPLAPHARM France, based in Levallois-Perret, a subsidiary of the CHEPLAPHARM Group from Greifswald/Germany, in April 2024. The previous Managing Director of CHEPLAPHARM France, Isabelle Dalle, is retiring. Caroline Jacquin, an experienced pharmaceutica [ … ]

Binningen, January 18, 2024   The CHEPLAPHARM Group acquires the global rights to Roaccutane® from Roche, thereby strengthening its dermatological portfolio. The medicine, which is based on the active ingredient isotretinoin, is used to treat severe acne.   CHEPLAPHARM, a leading purchaser of originator products from research-based pharmaceutic [ … ]